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1. ABSTRACT  
 
Elevated levels of low density lipoproteins (LDLs) cause atherosclerotic disease, and proteomic analyses have found 
that these lipoproteins are endowed with prenylcysteine lyase. This systematic review summarizes current understanding of this 
enzyme, now known as prenylcysteine oxidase 1 (PCYOX1), which hydrolyzes the thioether bond of prenylcysteines in the final 
step in the degradation of prenylated proteins, releasing hydrogen peroxide, cysteine and the isoprenoid aldehyde. Despite the 
high variability of the PCYOX1 gene, no polymorphism has yet been associated with any disease. The liver, which is responsible 
for vehiculization of the enzyme in lipoproteins, is one of the main organs responsible for its expression, together with the 
gastrointestinal tract, kidney, male reproductive tissue and muscle. Moreover, although hepatic mRNA expression is sensitive to 
diet and hormones, the repercussion of these changes in LDLs containing PCYOX1 has not been addressed. One consequence of 
its elevated activity could be an increase in hydrogen peroxide, which might help to propagate the oxidative burden of LDLs, 




 Lipids play a crucial role in organ homeostasis and, given their insolubility in the aqueous environment of plasma, 
require a sophisticated lipoprotein transport mechanism to move between tissues. Plasma lipoproteins can be separated into 
chylomicrons, very low-density lipoproteins (VLDLs), low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs), in 
order of increasing floating density, by ultracentrifugation. VLDLs, which are initially assembled in the endoplasmic reticulum of 
hepatocytes and further lipidated in the Golgi, are secreted into the circulation. VLDLs contain apolipoprotein B100 (APOB100) 
as the structural apolipoprotein and acquire other apolipoproteins (APOA1, APOA2, APOA4, APOC1, APOC2, APOC3 or 
APOE) once in the plasma. VLDLs transport triacylglycerols (TGs) from the liver to peripheral tissues, where lipoprotein lipase 
hydrolyzes the TGs to release non-esterified fatty acids for use as an energy source, leaving behind VLDL remnant particles. 
When these remnants are hydrolyzed by hepatic lipase, the resulting particles are known as LDLs. The latter, which are 
particularly enriched in cholesterol, are subsequently internalized by interaction with the LDL receptor and provide cholesterol to 




number of studies have proved that elevated levels of LDLs cause atherosclerotic cardiovascular disease (2) and should therefore 
be a treatment target (3). 
  
The fact that the non-APOB proteins present in LDL might modulate interactions with other proteins has prompted a 
series of proteomic analyses aimed at characterizing these minority proteins and their potential role in promoting or retarding 
LDL atherogenicity (4). Thus, using liquid isoelectrofocusing and polyacrylamide electrophoresis together with mass 
spectrometry, Banfi et al. proved that LDLs contain previously described apolipoproteins such as APOB100, APOA1, APOA4, 
APOE, APOJ and APOH. These authors also identified new proteins such as APOM, APOD, orosomucoid, retinol binding 
protein, paraoxonase 1 and prenylcysteine lyase (5). 
 
Prenylcysteine lyase (PCL1), the current recommended name of which is prenylcysteine oxidase 1 (PCYOX1), is also 
known as KIAA0908 or UNQ597/PRO1183. This enzyme is able to cleave the thioether bond of prenylcysteines in prenylated 
proteins, releasing a free cysteine and the aldehyde of the isoprenoid in what could be the final step in the degradation of 
prenylated proteins (6, 7). According to the International Union of Biochemistry and Molecular Biology, it is classified as an 
oxidoreductase that acts on donors containing a sulfur group, with oxygen being the acceptor (EC 1.8.3.5.) (8). Prenylated 
proteins may contain either a 15-carbon isoprenoid residue (farnesyl) or its 20-carbon counterpart (geranylgeranyl) covalently 
attached to cysteines located at or near their carboxyl end. Studies with the purified bovine enzyme showed that both 
farnesylcysteine and geranylgeranylcysteine can act as substrates (6). Prenylated proteins represent 2% of all cellular proteins, 
therefore an enzyme that is able to remove the isoprenoid residues in mammalian cells may play an important role in their 
normal turnover and open up the possibility of better characterizing their regulation. Moreover, the presence of this protein in 
plasma lipoproteins (5, 9) has increased interest in it, thus meaning that its wide spectrum of action and its poorly known 
regulation warrant further research in the near future. 
 
Although PCYOX1 was first discovered in 1997 (6), very little information has been published since then. The present 
report adheres to systematic review guidelines (10) and data were collected according to the criteria shown in Figure 1. The 
search in Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/) using the Key Words (PCYOX1 and PCL1) identified 19 hits between 
November 1945 and 08 June 2017. An additional search in electronic databases was also carried out. The combined information 
from both sources formed the basis of this review. 
 
3. HUMAN PCYOX1 GENE 
 
The PCYOX1 gene is located in the forward strand of chromosome 2, specifically in the 2p13.3. position, and has a 
length of 23,805 base pairs (bp). Classically, it was thought to contain six exons and five introns (11-13), although new high-
throughput technologies of RNAseq have identified three additional exons (14). 
 
3.1. Gene polymorphisms 
A total of 1610 single nucleotide polymorphisms (SNPs) have been found for the PCYOX1 gene to date, with 387 of 
these in the protein coding DNA (12). As can be seen from Table 1, the majority of SNPs in this particular region correspond to 
missense variations and coding sequence variants. No experimental evidence has been provided to establish the pathological 
significance of those variants described by the Exome Aggregation Consortium. Other sources of genomic variability present in 
this gene include copy number variations (21), short tandem repeats (19), inversions (2) and insertions (7) (16). Only four copy 
variations (nsv2776363, nsv2775326, nsv2772356, nsv533349) have been found to be associated with cytogenetics 
abnormalities, and no further validation has been carried out to assess their pathological contribution. Whether the high 
variability found in this gene in population studies translates into activity, and its consequences as regards the properties of 
LDLs, remains an open question at this stage. 
 
3.2. Hepatic PCYOX1 transcripts 
Since hepatic expression is responsible for the vehiculization of PCYOX1 in lipoproteins, only the expression of this 
organ will be discussed herein. However, this gene shows a nearly ubiquitous expression pattern (Figure 2), with the endocervix 
and testicles being the highest and the lowest expressing tissues, respectively (14). 
  
In the liver (Figure 3A), the PCYOX1 gene encodes for eight transcripts (14) generated by five different transcription 
start sites and alternative splicing. Only five of these codify for a protein (17). PCYOX1-001 has a length of 5345 bp distributed 
over six exons. Its open reading frame is 1515 bp and generates the isoform 1 of 505 amino acids, which is recognized as a 
canonical sequence (18). PCYOX1-002 has a length of 2959 bp distributed over six exons and generates a protein of 293 amino 
acids. PCYOX1-003 has a length of 556 bp distributed over four exons and generates a protein of 129 amino acids. PCYOX1-004 
has a length of 648 bp distributed over four exons and generates a protein of 154 amino acids. PCYOX1-006 has a length of 957 
bp distributed over five exons and generates a protein of 209 amino acids. No annotation has been given to two transcripts found 
by next generation sequencing, although they could also be translated into protein since they use the transcription start site of 
transcripts PCYOX1-004 and PCYOX1-006. A Western analysis using high sensitive detection revealed the hepatic expression of 




than expected based on their amino acid numbers, although this was not the case for PCYOX1-003 and PCYOX1-004. Future 
research will be required to establish the role of these isoforms in hepatic metabolism, and which of them is carried out by LDLs. 
 
3.3. Hepatic PCYOX1 transcriptional regulation 
Once again, the information regarding the liver will be considered using the HepG2 cell line as one of the most widely 
studied for this purpose. As mentioned above, the PCYOX1 gene has five potential transcription start sites. Four TATA-boxes, 
located in positions (-701.-685, -661.-645, -638.-615 and -450. -434) (19), could be used by RNA polymerase to start 
transcription. According to the data retrieved from the Genome server from UCSC (20), and shown in Figure 4, there is a high 
frequency of repetitive elements (long interspersed nuclear elements (LINEs), short interspersed nuclear elements (SINEs) and 
retrotransposons (LTRs)) throughout the gene. The regulatory mechanisms of these elements are totally unknown. 
 
Using the ENCODE database (21), the information in which is based on experimental observations, eight transcription 
factors modulating PCYOX1 expression in HepG2 were found (see Table 2). Most of these participate in general cell processes, 
modulating a wide range of transcription factors, and have ubiquitous expression (14, 22). As shown in Figure 5A, they bind to a 
region found in the third intron. A closer observation of the third intron (Figure 5B) reveals that all of these bind within a region 
spanning 400 bp (70,497,100-70,496,700 of chromosome 2). Despite the breakthrough that represents the ENCODE project, it 
remains difficult to offer a complete picture of the transcription factors that may be recruited to this gene under numerous 
biological circumstances.  
 
To investigate the changes in PCYOX1 hepatic expression inadvertently reported by different authors using 
transcriptomic analyses, a search for these changes was carried out in the publically available Genome Expressed Omnibus (23). 
The results are summarized in Table 3. As can be seen, the mRNA levels of this gene were increased in mice lacking caspase 1, 
NADH-cytochrome P450 reductase, stearoyl-coA desaturase, SIRT1, glycerol kinase, retinoblastoma protein, Mdr2, Dicer1, in a 
model of progeria and in mice overexpressing lipin-1 beta. In contrast, the absence of Pdss2, Il4 and Il-13, suppressor of cytokine 
signaling 3, HNF4A or GBA decreased Pcyox1 expression. Some dietary conditions, such as depletion of polyunsaturated fatty 
acids or dietary palatinose, also decreased its expression, while a ketogenic diet increased it. Likewise, an increase was reported 
in concanavalin-induced hepatitis, although alcohol-induced hepatitis had the opposite effect. A decreased expression was found 
following administration of glucocorticoids, perfluorooctanoic acid or an increase in hepatic Pcyox1 hormone expression. Using 
Apoe-deficient mice, we did not observe any changes upon feeding a diet containing nuts (24) or following squalene 
administration to wild-type mice (25). These findings indicate that hepatic Pcyox1 expression has a complex effect in terms of 
expression regulation, that diet and hormones are important elements, and that the effect of these changes in lipoproteins requires 
future research. 
 
3.4. Hepatic PCYOX1 post-transcriptional regulation 
Bioinformatics tools allow interactions of the murine Pcyox1 gene with microRNA to be predicted (26). According to 
the obtained results, 13 miRNAs showed a high score for this interaction. Of these thirteen putative miRNAs, only Mir124a-2, 
Mir3474, Mir5112 and Mir3473d were found in the liver at a low level of expression. The presence of hepatic miRNAs 
regulating translation of Pcyox1 mRNA adds a new level of complexity to this regulation and widens PCYOX1 levels in 
lipoproteins when those miRNA might undergo changes.  
 
4. HEPATIC PCYOX1 PROTEIN 
 
As already mentioned, the canonical PCYOX1-001 mRNA codes for a 505 amino acid protein. This 505-amino acid 
flavin adenine dinucleotide (FAD)-dependent thioether monooxygenase was found to have a molecular mass of 63 kDa when 
first isolated from bovine brain membranes (6), with the same size being found in mouse liver (Figure 3B). In contrast to mRNA 
expression levels, the liver is one of the highest expressers of this protein together with muscle, the gastrointestinal tract, kidneys 
and male reproductive tissue (Figure 6) (27, 28). 
  
As regards its cellular location, PCYOX1 seems to be mainly found in lysosomes (18), although it can also be exported 
to plasma lipoproteins secreted by the liver, such as VLDL and its metabolic product LDL (9). Interesting hypotheses may 
emerge in the future regarding this hepatic lysosomal presence as a result of recycling of LDL particles in the endolysosomal 
compartment or a direct movement of the enzyme to this organelle. These processes need to be studied in depth. 
 
4.1. Post-translational modifications (PTMs) 
The discrepancy between the theoretical prediction for a 505-amino acid protein (56 kDa) and the observed molecular 
mass (63 kDa) could be due to glycosylation, as was proved using lectin-affinity chromatography in brain (29). Furthermore, a 
post-translational N-glycosylation in plasma could also take place, as evidenced by digestion with peptide-N-glycosidase F (30). 
In fact, computational analyses revealed the existence of several motifs capable of being GalNAc O- or N-Glycosylated, as 
reflected in Table 4. When recombinant prenylcysteine lyase was produced, analysis of both the recombinant and native enzymes 





Glycosylation is not the only post-translational modification that this protein can undergo. Using different bioinformatics 
tools, we have predicted the existence of additional motifs susceptible of undergoing PTMs (acetylation, phosphorylation, 
nitrosylation, palmitoylation, succinylation, sumoylation and ubiquitination). A summary of these can be found in Table 4, and 
most are located on the prenylcysteine lyase domain (Figure 7). However, experimental confirmation of these modifications is 
lacking and their relevance as regards LDL activity needs to be addressed in the future. 
 
4.2. Protein structure and function 
PCYOX1 has three domains: an N-terminal signal peptide of 23 amino acids, an NAD(P)-binding Rossmann-like 
region (amino acids 39-106) and a prenylcysteine lyase domain (amino acids 128-496), as represented in Figure 7. The latter two 
are believed to exert the redox activity (31). Indeed, mutagenesis of Y455, E468 and M469 by alanines resulted in a loss of 
activity . These residues are preserved between humans and mice, thus suggesting that they are critical to the action of this 
enzyme in different species. 
 
As it is a flavin adenine dinucleotide (FAD)-dependent thioether monooxygenase, PCYOX1 does not require NADPH 
as cofactor to catalyze S-oxidation of thioethers, in contrast to other enzymes such as cytochrome P450- and flavin-containing 
monooxygenases. Both farnesylcysteine and geranylgeranylcysteine could be its substrates, although Vmax has been reported to 
be twice as high with the former (6). However, prenylcysteine substrates must possess a free amino group since N-acetylated 
prenylcysteines and prenyl peptides are not used by PCYOX1 (6). As shown in Figure 8, it cleaves prenylcysteines to cysteine 
and a C-1 aldehyde of the isoprenoid moiety (farnesal in the case of C-15). The enzyme utilizes a noncovalently bound flavin 
cofactor, requires molecular oxygen and releases hydrogen peroxide (7). The reaction proceeds by way of a sequential 
stereospecific mechanism in which the pro-S hydride of the farnesylcysteine is transferred to FAD to initiate the reaction and 
cysteine production is one of the primary rate-limiting steps in the process (33). In this way, the metabolic challenge of the 
degradation of prenylated proteins is solved by breaking the stable thioether bond of the modified cysteine (34). However, the 
release of hydrogen peroxide is a source of oxidative stress that may enhance damage in situations with increased enzyme 
activity. 
 
4.3. Protein interactions 
PCYOX1, as an enzyme, interacts with a vast number of different proteins and plays an important role in various cell 
processes. Although the methods used to discover these interactions (co-sedimentation, anti-tag co-immunoprecipitation or yeast-
two-hybrid) do not allow us to unveil its biological role (11, 35-37), this can be inferred by determining the characteristics of the 
proteins with which PCYOX1 interacts, as reflected in Table 5. Thus, it can participate in modulating the respiratory chain, cell 
death, cell signaling, movement and transport, metabolism and protein degradation. In fact, overexpression of PCYOX1 in COS-
7 cells has been found to be particularly cytotoxic (38). Its interaction with other chaperones is especially remarkable, with 
PCYOX1 acting as a co-chaperone or needing them for correct folding. Along the same lines, it should be pointed out that the 
interaction of PCYOX1 with the ubiquitination machinery and predicted ubiquitination sites could represent a means of 
controlling the half-life of PCYOX1. 
 
Although not much is known about the involvement of PCYOX1 in disease processes, some of these interactions may 
suggest that it plays an important role in diseases such as cancer, due to the role of numerous proteins in important aspects of cell 
life. For instance, dysregulation of PCYOX1 may affect cell death via the CLU as a possible previously unexplored cause of 
cancer. In addition, a failure to interact with NDUFV2 could modulate the phenotypes of mitochondrial or other diseases in 
which this organelle has a profound influence. An important effort is therefore required to determine the influence of the high 
variability of PCYOX1, described in Table 1, on its ability to interact with other proteins and the putative consequences of these 
potential failures.  
 
PCYOX1 can also be regulated by a large number of compounds (Table 6) (39) that can interact directly with the protein. In fact, 
docking assays carried out with the amino acid residues 36-70 of PCYOX1, which includes the majority of the NADP-binding 
domain as a target in well-conserved 2GV8, a crystalized protein, and three ligands (cyclosporine A, rosiglitazone and 
paracetamol), revealed that some regions are able to interact (40). These regions might form part of the active or regulatory sites. 
However, this would require crystallization of PCYOX1 and further folding, activity and stability studies to support this 
hypothesis. 
 
5. PCYOX1 IN PHYSIOLOGY AND DISEASE 
 
5.1. Lipoproteins 
As indicated in the introduction, proteomic technologies using 2-D electrophoresis and MALDI-TOF/TOF analyses 
have confirmed the presence of PCYOX1 in lipoproteins in healthy volunteers. Two isoforms were described as new VLDL-
associated proteins (9). Using liquid-phase isoelectrofocusing of LDL proteins, prenylcysteine lyase (PCL1), as named by the 
authors at the time, was also found to be a component of these lipoproteins, and their incubation with farnesylcysteine showed 
that the enzyme was active, releasing hydrogen peroxide. Banfi et al. showed that VLDL displayed a higher activity than LDL or 
HDL. Further support for this activity was obtained by proving that farnesol, a PCL1 inhibitor, decreased hydrogen peroxide 




second ultracentrifugation was unable to remove it. These facts indicate that the enzyme is a constitutive component of LDL (5), 
and therefore that LDLs are able to generate the potent oxidant hydrogen peroxide as a result. In an independent study, the 
presence of PCYOX1 protein was analyzed in VLDLs and LDLs purified from normolipidemic pooled plasmas by 
ultracentrifugation in NaBr or iodixanol gradients and proteomic analysis. Both fractions were found to contain the same amount, 
and the PCYOX1 levels correlated positively with those of APOA1 (41). Using a large number of subjects (230 volunteers), 
Dasthy et al. also prepared VLDLs and LDLs by ultracentrifugation and analyzed their constituent proteins by nano liquid 
chromatography-tandem mass spectrometry, confirming that PCYOX1 was associated with both VLDLs and LDLs (42). In a 
proteomic analysis of electronegative LDLs from normolipidemic subjects, no PCYOX1 was reported (43). No report has been 
found for Lp(a) and PCYOX1. Taken together, these observations indicate that PCYOX1 is a component of VLDLs and LDLs, 
its origin is hepatic, and the H2O2-generating role of this enzyme in LDLs will require more attention in future research as regards 
the role of atherogenic lipoproteins in atherogenesis. Equally, more research is needed to characterize specific LDL subtypes and 
the role of this enzyme in physiology and disease.  
 
5.2. Pcyox1-deficient mice  
To establish the importance of this enzyme at a biochemical or physiological level, Beigneux et al. created Pcly-
deficient mice. As expected, the absence of enzyme resulted in an accumulation of both farnesylcysteine and 
geranylgeranylcysteine in the brain and the liver, with no further pathological consequences, in thirty tissues from 4- and 10-
month-old Pcly-deficient mice analyzed using routine histologic stains (32). No observation of liver by electron microscopy or 
fluorescence to detect the accumulation of fluorescent material, which is usually observed in other lysosomal storage diseases, 
was carried out. Blood chemistry, including calcium, phosphate, glucose, cholesterol, triglycerides, alanine aminotransferase, 
aspartate aminotransferase, and creatinine, was normal in these mice, and serum lipid levels in the Pcly-deficient and wild-type 
mice did not differ on a high-fat diet either. The authors raised the possibility that the paralogous gene, Pcyox1l, could 
compensate for the absence of PCYOX1, thus explaining why such a benign phenotype was observed, but this aspect was not 
explored further. At that time the enzyme was not suspected to be carried in LDLs, therefore no analysis was carried out in this 
regard. Therefore, characterization of these mice in terms of LDL oxidative properties and atherosclerosis development is a gap 
that still needs to be filled. 
 
5.3. PCYOX1 and the liver 
Mice lacking interstitial cells of Cajal (Sl/Sld and W(LacZ)/Wv), the so-called pacemaker cells of the gut, showed 
significantly lower expression of hepatic Pcyox1 compared to wild-type mice (38). In a study of its nutritional regulation, our 
group observed no significant changes in hepatic Pcyox1 expression after the consumption of a nut-containing diet in Apoe-
knockout mice (24) or following squalene administration (25). However, the changes observed following depletion of N-3 
polyunsaturated fatty acids (Table 3) indicate that some nutritional regulation may exist. 
 
5.4. PCYOX1 gene and cancer 
Next-generation sequencing of tumors has shown a large number of mutations in this gene (Figure 9), with the last exon 
being the DNA segment that accumulates the highest ratio of mutations in the tumors analyzed (44). However, no association 
studies have linked cancer to PCYOX1 gene variations to date (16), or to the protein variations considered. Despite this, different 
changes in gene expression have been observed in several tumors, as can be seen from Table 7. In this regard, pancreatic 
adenocarcinoma and osteosarcoma showed the highest increases, followed by large cell lung carcinoma, adenocarcinoma of the 
prostate, poorly differentiated hypernephroma, acute lymphoblastic leukemia, renal adenocarcinoma, ovarian cancer, 
adenocarcinoma of the colon, breast cancer, adenocarcinoma of the lung, and melanoma. In contrast, malignant mesothelioma 
showed the highest decrease, followed by pancreatic ductal adenocarcinoma, ovarian cancer, medulloblastoma, fibroadenoma, 
vulvar intraepithelial neoplasia, and clear cell renal carcinoma. In light of these findings, further studies are required to establish 
the role of this protein in this field and, as a consequence, of the catabolism of prenylated proteins in tumor development and 
evolution. The increase in hydrogen peroxide, and the consequent oxidative stress that its elevated activity may produce, should 
also be studied. 
 
5.5. PCYOX1 and neurodegenerative diseases 
Prenylcysteine lyase (PCYOX1) was found amongst the major glycoproteins from brains obtained from necropsies of 
Alzheimer’s patients by using lectin-affinity and ion-exchange chromatographic analyses, followed by further separation using 
SDS-polyacrylamide gel electrophoresis (29). However, more experimental work is needed to determine the significance of this 
finding in this disease. 
 
5.6. PCYOX1 and obesity 
In an effort to investigate the differential gene expression of visceral and subcutaneous fat depots, Poussin et al. fed 
C57Bl/6 mice a high-fat diet for 6 months and mice with different body weights but similar levels of glucose intolerance were 
then treated with vehicle or rimonabant for one month to normalize body weight. Although not reported by the authors, we 
looked for the gene in GEO using deposition number GSE11790. An increased expression of Pcyox1 mRNA was observed in 
visceral but not in subcutaneous adipose tissue of mice receiving the high-fat diet. This increase was corrected following 
rimonabant administration (45). A hypothetical consequence of this increase would be an additional source of hydrogen peroxide 




tissue with several complications of obesity. This interesting aspect requires further confirmation with new experiments and 
analyses of this enzyme in this particular setting with important repercussions in cardiovascular diseases. 
 
6. CONCLUSIONS  
 
The presence of PCYOX1 in low-density lipoproteins may aggravate LDL atherogenicity. In this regard, PCYOX1 acts 
as an enzyme that hydrolyzes prenylcysteines to cysteine and a C-1 aldehyde of the isoprenoid moiety. The enzyme utilizes a 
noncovalently bound flavin cofactor, requires molecular oxygen, and releases hydrogen peroxide. Two hypothetical situations 
may be envisioned in atherogenesis: first, the presence of LDLs carrying PCYOX1 in the subendothelial space may be more 
atherogenic since they can catabolize the final products of prenylcysteine-containing proteins, releasing the isoprenoid aldehyde 
and hydrogen peroxide. Second, these two products, which are not conveniently neutralized, may complicate the scenario, with 
the former possibly modifying the lysine groups of proteins, thus rendering them non-functional, and the second may increase 
oxidative damage. This would help to propagate cell damage following a primary insult in which these PCYOX1-containing 
LDLs are recruited. New research is therefore needed to determine whether this enzyme is particularly present in electronegative 
LDLs or in Lp(a). Since the liver is the primary source of this enzyme, new endeavors should be directed towards characterizing 
the hepatic regulation thereof and its translation into LDL changes. Moreover, many of the genetic variants should be 
characterized as regards this enzyme activity. Simplified assays should be developed to establish the role of the enzyme as a 
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Figure 1. Flow chart displaying the information collection process. Two different sources of data were used: data from online 
bioinformatics databases and a search in Pubmed. EndNote X7 (Thomson Reuters, New York, NY) 
Figure 2. Gene expression for PCYOX1 in 53 different tissues from GTEx RNA-seq of 8555 samples (570 donors). Expression 
values are shown as log10 of RPKM (reads per kilobase of transcript per million mapped reads), calculated from a gene model 
with isoforms collapsed to a single gene. Box plots are shown as median and 25th and 75th percentiles (14). 
 
Figure 3. Transcript (A) and protein (B) isoforms of PCYOX1 found in the liver using next-generation sequencing (14). The 
annotation is in accordance with that used in (17). Panel B shows the position of molecular markers. 
 
Figure 4. Schematic representation of ENCODE information regarding regulatory elements of PCYOX1 gene. The presence of a 
CpC island of 1131 bp and repetitive elements is shown.  
 
Figure 5. Analysis of positional binding of transcription factors to the PCYOX1 gene in HepG2 cells. A: General overview of 
Genome Data viewer from the NCBI server (46) with information from ENCODE (21). Only transcription factors whose signals 
were higher than the input IgG from either rabbit or goat, which is considered to represent background noise, were selected. B: 
Detailed representation of the third intron region where transcription factors bind. GEO accession numbers are shown. 
 
Figure 6. PCYOX1 protein and mRNA in different human tissues. Protein-expression scores are based on a best estimate of the 
“true” protein expression from a knowledge-based annotation. For genes where more than one antibody was used, a collective 
score was set displaying the estimated true protein expression. mRNA is expressed as number of transcripts per million reads. 
Reproduced with permission from (28). 
 
Figure 7. Scheme showing PCYOX1 domains and distribution of post-translational modifications (PTMs) and putative 
secondary structure. A: the graphic shows the three domains, found between amino acids 1-23, 39-106 and 128-501 (31). B: 
location of PTM and prediction of secondary structure. In this representation, red denotes a potentially disordered region and blue 
a probably ordered region. In the hydropathy analysis, red represents hydrophobicity and blue hydrophilicity (47).  
 
Figure 8. Reaction catalyzed by PCYOX1. Adapted from (7), reproduced with permission from the American Society for 
Biochemistry and Molecular Biology. 
 
Figure 9. Distribution of mutations along the PCYOX1 gene found in tumor cells and the number of tumors analyzed to 
determine changes in this gene expression. Graphics generated using the Wellcome Trust Sanger Institute server (44). 
 
Table 1. DNA changes observed in the coding region of the PCYOX1 gene in different human populations.  
 Type of variation Number found 
Coding sequence variant 76 
Frameshift variant 16 
In-frame deletion 3 
Mis-sense variant 200 
Mis-sense variant splice region variant 4 
Protein altering variant 1 
Splice region variant  in coding sequence variant 1 
Start lost 3 
Stop gained 15 
Stop gained  frameshift variant 1 
Synonymous variant 67 
A summary of protein variations found in Ensemble (12) and corresponding to the Exome Aggregation Consortium (15). 
 
Table 2. Transcription factors found to control PCYOX1 gene expression in HepG2 (14, 21, 48) 
Transcription factor Biology process Tissue expression 
ARID3A 
Member of the ARID (AT-rich interaction domain) family involved in 




Basic helix-loop-helix protein believed to be involved in the control of 
cell differentiation. 
Ubiquitous expression 




COREST Demethylation of Lys-4 of histone H3  Ubiquitous expression 
HNF4A Nuclear transcription factor critical for liver development Colon, ileum, kidney, liver, pancreas 
Max 
Proliferation and apoptosis thought H3 Lys-9 methyl-transferase 
complex 
Ubiquitous expression 
MAZ Transcription factor involved  in transcription initiation and termination Ubiquitous expression 
SMC3 Chromosome cohesion during cell cycle and in DNA repair Ubiquitous expression 
 
 
Table 3. Changes in hepatic Pcyox1 expression according to Genome Expressed Omnibus data bank and Array express.  
Experimental condition Type of change Accession number 
Genetic conditions 
 Caspase-1 deficiency effect on fasted liver Increased GDS4922 
 NADH-cytochrome P450 reductase deletion effect on 
the liver 
Increased GDS1349 
 Stearoyl-CoA desaturase 1-deficient mutants on a very 
low-fat, high-carbohydrate diet 
Increased GDS1374 
 SIRT1 deficiency effect on the liver Increased GDS3666 
 Glycerol kinase knockout effect on liver  Increased GDS1555 
 Retinoblastoma protein deficiency effect on fetal livers Increased GDS2757 
 Mdr2 knockout model of hepatocellular carcinoma at 
precancerous stages 
Increased GDS1990 
 Livers with Dicer1 deficient hepatocytes Increased GDS3685 
 Lmna G609G knock-in model of Hutchinson-Gilford 
Progeria Syndrome 
Increased GDS4490 
 LIGHT overexpressing T cells and a high fat diet effect 
on the liver 
Increased GDS3056 
 Lipin 1-beta overexpression effect on the liver Increased GDS2291 
 Murine Pdss2 liver-specific knockouts as a model of 
primary mitochondrial dysfunction Decreased GDS3454 
 IL-4 and IL-13 double mutant liver response to acute 
injury Decreased GDS5073 
 Suppressor of cytokine signaling 3 deficiency effect on 
the regenerating liver Decreased GDS3149 
 Hepatocyte nuclear factor 4 alpha knockout effect on the 
embryonic liver Decreased GDS1916 




 N-3 polyunsaturated fatty acid depletion effect on the 
liver Increased GDS4796 
 Ketogenic diet effect on the liver Increased GDS2738 
 Dietary palatinose effect on liver Decreased GDS5435 
Pathological conditions 
 Concanavalin A-induced fulminant hepatitis model 
Increased GDS3752 
 Alcoholic hepatitis in Homo sapiens 
Decreased GDS4389 
 Oxidative stress and Snell dwarf liver 
Decreased GDS683 
 Pharmacological agents   
 Glucocorticoid effect on the female and male liver 
Decreased GDS5036 and 5035 
 High doses of perfluorooctanoic acid effect on fetal 
liver Decreased GDS3410 
 Sex-dependent and growth hormone-dependent gene 
expression in rat Decreased GDS862 
https://www.ncbi.nlm.nih.gov/geoprofiles and https://www.ebi.ac.uk/arrayexpress/ . Accessed on 12 February 2017 
 
Table 4. Post-translational modifications of human PCYOX1 and participant amino acids 
Modification Modified amino acids Prediction server References 
Glycosylation No reports (*) DictyOGlyc (49) 
GalNAc O-glycosylation Thr (398), Ser (322) NetOGlyc (50) 
N-Glycosylation Asn (196, 288, 323, 353)  NetNGlyc (51) 
N-Glycosylation Asn (196, 288, 323, 353)  NetNGlyc (51) 
Acetylation 
 




Mannosylation No reports (**) NetCGlyc (54) 
Phosphorylation Thr (47, 77, 198, 286, 299, 303, 308, 325, 345, 373, 407, 414, 503), Ser (11, 24, 90, 
109, 110, 131, 149, 171, 177, 178, 209, 239, 259, 266, 267, 273, 276, 301, 305, 322, 
358, 382, 409, 419, 435, 465), Tyr (51,  85, 174, 191, 297, 308, 339, 403, 425, 427, 








S-nitrosylation Cys (24, 242, 258, 445) GPS-SNO (57) 
Palmitoylation Cys (20, 22, 24) CSS-Palm 4.0. (58) 
Succinylation Lys (415, 430)  (56) 
Sumoylation Lys (62, 349, 502) GPS-SUMO 2.0. (59) (53) 




(60)  (61, 
62) 
*DictyOGlyc reports no results, so there are no probable glycosylation sites in the O-residues of PCYOX1. ** No results were 
found using NetCGlyc. Mannosylation is uncommon in mammal proteins. All predictions were made using bioinformatics tools 
that checked the homology of PCYOX1 protein domains with experimental databases for the PTMs. The sequence used to predict 
the PTMs of PCYOX1 was the canonical sequence of the isoform PCYOX1-001. 
 
Table 5. Protein interactions of human PCYOX1 and the cell processes involved 
Proteins Biology process 
ERP27, FKBP7, FKBP14  Chaperones 
CLU Cell death 
NENF, RHOBTB3, ANTXR1, PLAUR, DLK1, ISLR, TRAC Cell signaling 
LAMP1, SLC9A3R1, UBAC2, TRDN Cell transport 
DYNC2LI1 Cell movement 
PBLD,  FDPS, BLVRA, ENTPD4, PLTP Metabolism 
NDUFV2 Respiratory chain 
FOXRED2, UBC Ubiquitination 
These interactions were discovered by co-sedimentation, co-immunoprecipitation, and yeast-two hybrid system (11, 35-37). 
 
 
Table 6. Regulation of PCYOX1 expression with different chemical compounds. 
Type of agents Compounds 
Toxic agents 
2,3,7,8-Tetrachlorodibenzodioxine, 4'-diaminodiphenylmethane benzopyrene, benzene, 2,6-dinitrotoluene, paraquat,  bisphenol 
A, aroclor 1254, crocidolite asbestos, N-methyl-4-phenylpyridinium, ammonium chloride, tributylstannane, 3-isobutyl-1-methyl-
7H-xanthine,  butanal, flutamide,  silicon dioxide 
Toxins Aflatoxin B1 
Immunosuppressor Cyclosporine A 
Antidiabetic Rosiglitazone 
Adrenaline analogous 3,4-Methylenedioxymethamphetamine 
ROS tert-Butyl hydroperoxide, 4-hydroxynon-2-enal  
Antitumor Methotrexate 
PPARα Pirinixic acid 
Non-steroid anti-inflammatory Paracetamol 
Antibiotics Gentamycin 
Anti-epilepsy drug Valproic acid, phenytoin 
Metals Zinc, nickel, copper(II) sulfate, titanium dioxide, lead diacetate, potassium dichromate 
Hormones Testosterone enanthate, dexamethasone 
Interactions between PCYOX1 and different organic and inorganic compounds as drugs and metabolites. All of them were 
experimentally discovered by different research groups (22, 23, 39) 
 
Table 7. Changes of PCYOX1 gene expression in different tumors 
Type of tumor Log2-fold change 
Pancreatic adenocarcinoma 3.1. 
Osteosarcoma 3.1. 
Large cell lung carcinoma 3 
Adenocarcinoma prostate 2.7. 
Poorly differentiated hypernephroma 2.6. 
Acute lymphoblastic leukemia 2.6. 
Renal adenocarcinoma 2.5. 
Ovarian cancer 2 
Adenocarcinoma of colon 1.9. 
Breast cancer 1.9. 
Adenocarcinoma of lung 1.6. 
Melanoma 1.3. 
Clear cell renal carcinoma -1.2. 
Vulvar intraepithelial neoplasia -1.2. 
Fibroadenoma -1.4. 
Medulloblastoma -1.7. 
Ovarian cancer -1.8. 
Pancreatic ductal adenocarcinoma -1.9. 
Malignant mesothelioma -2.5. 
A summary of data found in EMBL-EBI (63) and Wellcome Trust Sanger Institute (44) servers 
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